image: CeMM PI Christoph Bock
Credit: Bubu Dujmic / CeMM
(Vienna, 23 June 2026) With this new grant, Christoph Bock has now received an ERC Starting, Consolidator, and Advanced Grant in direct succession – a rare and exceptional achievement. Supported by his previous ERC grants, Bock’s research group developed breakthrough technologies for genetic screening (including the CROP-seq method for high-content CRISPR screens) and advanced computational methods (including the CellWhisperer AI for chat-based analysis of single-cell data). Most recently, the team used CRISPR screening as a form of artificial evolution that makes CAR T cells more effective for the treatment of blood cancers – a discovery that is being prepared for clinical testing.
Building upon this prior work, the new ERC Advanced Grant tackles a harder challenge: making CAR T cells effective against solid tumors, which suppress the body’s immune response and can be hard to distinguish from healthy cells that must not be destroyed.
“Living drugs” for tumor therapy
In CAR T cell therapy, the patient’s own immune cells are genetically engineered to recognize and kill cancer cells. These reprogrammed cells become “living drugs” and have demonstrated tremendous efficacy against certain blood cancers. However, CAR T cells have struggled against solid tumors – including lung, breast, and colon cancer, which are among the leading causes of cancer-related deaths in Europe.
Next-generation CAR T cell designs
One reason is that solid tumors are remarkably good at hiding and defending. They create a hostile environment that weakens attacking immune cells. Another reason is that most solid tumors lack markers that would clearly distinguish them from healthy cells, meaning that a CAR T cell runs the risk of causing extensive collateral damage.
The Solid-CART project tackles both challenges. It combines CRISPR screens with mouse tumor models that harbor a fully functional immune system, seeking to discover genetic boosters of CAR T cell function. It further employs AI-based design of regulatory DNA to develop “two-factor authentication” for CAR T cells, restricting their killing to the tumor and thereby reducing dose-limiting toxicities elsewhere in the body.
Biomedical research with clinical relevance
The project will focus on HER2-positive lung, breast, and colon tumors. These are major causes of cancer death and exemplify the challenges of CAR T cell therapy against solid tumors. Although these tumors express a well-known protein and drug target (HER2), current anti-HER2 therapies are often insufficient, and CAR T cells cause dose-limiting toxicities by attacking HER2-positive healthy cells elsewhere in the body.
Following initial discovery and testing in mouse models, the Solid-CART project will validate the most promising CAR T cell designs against human tumor cells and prepare them for future evaluation in first-in-human clinical trials. Clinical translation of the new CAR T cell therapies will be pursued in close collaboration with Antonia Müller, Professor of Cell Therapy at the Medical University of Vienna.
Advancing frontier research
ERC Advanced Grants are among the most prestigious and competitive funding schemes in Europe. They are awarded to established scientific leaders with exceptional track records and support high-risk, high-gain research that has the potential to transform entire fields. These grants provide researchers with the freedom and long-term support needed to tackle some of the most difficult scientific challenges.
For CeMM, the award represents further recognition of the institute’s commitment to frontier biomedical research and its mission to translate scientific discoveries into better medicine.
###
The CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences is an international, independent and interdisciplinary research institution for molecular medicine under the scientific direction of Maria Rescignio. CeMM is oriented towards medical needs and integrates basic research and clinical expertise to develop innovative diagnostic and therapeutic approaches for precision medicine. Research focuses on cancer, inflammation, metabolic and immune disorders, rare diseases and aging. The Institute's research building is located on the campus of the Medical University and the Vienna General Hospital.
The Medical University of Vienna (MedUni Vienna) is one of the longest-established medical education and research facilities in Europe. With almost 8,600 students, it is currently the largest medical training center in the German-speaking countries. With more than 6,500 employees, 30 departments and two clinical institutes, twelve medical theory centers and numerous highly specialized laboratories, it is one of Europe's leading research establishments in the biomedical sector. MedUni Vienna also has a medical history museum, the Josephinum.
For further information please contact:
Wolfgang Däuble
Media Relations Manager / Science Writer
Phone +43-1/40160-70092
wdaeuble@cemm.at
CeMM
Research Center for Molecular Medicine
of the Austrian Academy of Sciences
Lazarettgasse 14, AKH BT 25.3
1090 Vienna, Austria
www.cemm.at